130 related articles for article (PubMed ID: 23564228)
1. Histology as a potential clinical predictor of outcome in advanced non-small-cell lung cancer treated with vinorelbine and mitomycin combination chemotherapy.
Wibmer T; Berghmans T; Kropf-Sanchen C; Lafitte JJ; Rüdiger S; Paesmans M; Blanta I; Scherpereel A; Stoiber KM; Rottbauer W; Sculier JP; Schumann C
Lung; 2013 Jun; 191(3):271-80. PubMed ID: 23564228
[TBL] [Abstract][Full Text] [Related]
2. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.
Wang YD; Ha MW; Cheng J; Zhang WL; Cong X; Tong CY; Sun J
Oncol Rep; 2012 Apr; 27(4):979-86. PubMed ID: 22179630
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy.
Kelly K; Chansky K; Mack PC; Lara PN; Hirsch FR; Franklin WA; Wozniak AJ; Edelman MJ; Williamson SK; Gandara DR
Clin Lung Cancer; 2013 Nov; 14(6):627-35. PubMed ID: 23910067
[TBL] [Abstract][Full Text] [Related]
4. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
Gebbia V; Galetta D; Riccardi F; Gridelli C; Durini E; Borsellino N; Gebbia N; Valdesi M; Caruso M; Valenza R; Pezzella G; Colucci G;
Lung Cancer; 2002 Aug; 37(2):179-87. PubMed ID: 12140141
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer.
Wibmer T; Kropf C; Merk T; Schumann C; Hombach V; Krüger S
Lung Cancer; 2008 May; 60(2):231-9. PubMed ID: 18006111
[TBL] [Abstract][Full Text] [Related]
6. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
[TBL] [Abstract][Full Text] [Related]
7. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.
Westeel V; Quoix E; Moro-Sibilot D; Mercier M; Breton JL; Debieuvre D; Richard P; Haller MA; Milleron B; Herman D; Level MC; Lebas FX; Puyraveau M; Depierre A;
J Natl Cancer Inst; 2005 Apr; 97(7):499-506. PubMed ID: 15812075
[TBL] [Abstract][Full Text] [Related]
8. Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: a prospective study.
Berghmans T; Gourcerol D; Lafitte JJ; Kotsori K; Paesmans M; Scherpereel A; Leclercq N; Sculier JP;
Lung Cancer; 2008 Sep; 61(3):378-84. PubMed ID: 18313792
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of vinorelbine, mitomycin C and cisplatin chemotherapy for advanced non-small cell lung cancer.
Kwon MR; Jeong TY; Yuh YJ; Kim SR
Korean J Intern Med; 2002 Dec; 17(4):240-4. PubMed ID: 12647638
[TBL] [Abstract][Full Text] [Related]
10. Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Français de Pneumo-Cancérologie'.
Pérol M; Guérin JC; Thomas P; Poirier R; Carles P; Robinet G; Kleisbauer JP; Paillotin D; Vergnenègre A; Balmes P; Touron D; Grivaux M; Pham E
Lung Cancer; 1996 Feb; 14(1):119-34. PubMed ID: 8696715
[TBL] [Abstract][Full Text] [Related]
11. Post-operative treatment with cisplatin and vinorelbine in Chinese patients with non-small cell lung cancer: a clinical prospective analysis of 451 patients.
Wang J; Liu F; Huang DX; Jiang B
Asian Pac J Cancer Prev; 2012; 13(9):4505-10. PubMed ID: 23167369
[TBL] [Abstract][Full Text] [Related]
12. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
13. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer.
Tan EH; Rolski J; Grodzki T; Schneider CP; Gatzemeier U; Zatloukal P; Aitini E; Carteni G; Riska H; Tsai YH; Abratt R
Ann Oncol; 2009 Jul; 20(7):1249-56. PubMed ID: 19276396
[TBL] [Abstract][Full Text] [Related]
14. UFT plus vinorelbine in advanced non-small cell lung cancer: a phase I and an elderly patient-directed phase II study.
Igishi T; Shigeoka Y; Yasuda K; Suyama H; Katayama S; Sugitani A; Matsumoto S; Yamamoto M; Ueda Y; Takeda K; Sumikawa T; Sako T; Kodani M; Hitsuda Y; Shimizu E
J Thorac Oncol; 2009 Mar; 4(3):376-82. PubMed ID: 19190514
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin and vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer.
Horvath L; Boyer M; Clarke S; Beale P; Beith J; Underhill C; Stockler M; Bishop J
Lung Cancer; 2001 May; 32(2):173-8. PubMed ID: 11325488
[TBL] [Abstract][Full Text] [Related]
16. Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer.
Farhat FS; Ghosn MG; Kattan JG
Cancer Chemother Pharmacol; 2015 Aug; 76(2):235-42. PubMed ID: 26024554
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine.
Krug LM; Miller VA; Filippa DA; Venkatraman E; Ng KK; Kris MG
Lung Cancer; 2003 Feb; 39(2):139-43. PubMed ID: 12581565
[TBL] [Abstract][Full Text] [Related]
18. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.
Berghmans T; Ameye L; Willems L; Paesmans M; Mascaux C; Lafitte JJ; Meert AP; Scherpereel A; Cortot AB; Cstoth I; Dernies T; Toussaint L; Leclercq N; Sculier JP;
Lung Cancer; 2013 Nov; 82(2):340-5. PubMed ID: 24007627
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
